Table 3.
Univariate analysis of factors associated with overall survival in MPE patients who underwent VATS talc pleurodesis
| Variables | Hazard ratio | 95% confidence interval | P value |
|---|---|---|---|
| Age (years) | |||
| <70 | 1.00 | ||
| ≥70 | 1.30 | 0.76–2.23 | 0.342 |
| Gender | |||
| Female | 1.00 | ||
| Male | 1.30 | 0.74–1.73 | 0.564 |
| Disease duration | |||
| <12 months | 1.00 | ||
| ≥ 12 months | 1.98 | 1.24–3.15 | 0.004 |
| Pleural fluid pH | |||
| <7.3 | 1.00 | ||
| ≥ 7.3 | 1.16 | 0.72–1.86 | 0.556 |
| Pleural fluid LDH (IU/l) | |||
| <1500 | 1.00 | ||
| ≥ 1500 | 1.63 | 0.86–3.09 | 0.139 |
| Neutrophil to lymphocyte ratio | |||
| <9 | 1.00 | ||
| ≥9 | 1.67 | 0.86–3.09 | 0.132 |
| Extra‐thoracic metastasis | |||
| Absent | 1.00 | ||
| Present | 1.97 | 1.27–3.07 | 0.003 |
| Preoperative chemotherapy | |||
| No | 1.00 | ||
| Yes | 3.44 | 2.13–5.54 | <0.001 |
| Preoperative radiotherapy | |||
| No | 1.00 | ||
| Yes | 4.19 | 2.35–7.49 | <0.001 |
| ECOG PS | |||
| 0–2 | 1.00 | ||
| 3–4 | 2.35 | 1.52–3.65 | <0.001 |
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; MPE, malignant plural effusion; PS, performance score; VATS, video‐assisted thoracic surgery.